John Bray, MD
Pulmonary Disease · Pensacola, FLNPI 1811972359
Payments from drug & device makers
Across 164 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Electromed, Inc.$530
- GSK$278
- Genentech USA, Inc.$191
- AstraZeneca$169
- Actelion Pharmaceuticals US, Inc.$157
- Boehringer Ingelheim$136
- plus $813 from 20 others
What the payments were for
- Food & beverage$2,274100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Electromed, Inc. | 52 | $530 |
| GSK | 17 | $278 |
| Genentech USA, Inc. | 13 | $191 |
| AstraZeneca(2 entities) | 11 | $169 |
| Actelion Pharmaceuticals US, Inc. | 15 | $157 |
| Boehringer Ingelheim | 9 | $136 |
| AbbVie(2 entities) | 5 | $134 |
| Philips North America LLC | 5 | $74 |
| Inspire Medical Systems, Inc. | 3 | $69 |
| Merck | 4 | $68 |
| Sanofi | 4 | $64 |
| Insmed, Inc. | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 6 | $58 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Vapotherm Inc | 1 | $27 |
| Mylan Specialty L.p. | 1 | $25 |
| Grifols USA, LLC | 1 | $21 |
| 3b Medical, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Resmed Corp | 1 | $17 |
| Gilead | 1 | $13 |
| Bayer | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Cook Medical LLC | 1 | $13 |
| Johnson & Johnson | 2 | $13 |
How this compares
$2,274 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Pensacola
- Peter BerczPensacola$1.3M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.